AA
TNYA icon

AlphaMark Advisors’s Tenaya Therapeutics TNYA Stock Holding History

AlphaMark Advisors’s Portfolio TNYA Stock Details TNYA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		$15K Buy
10,600
+10,500
+10,500% +$23.5K 0.01% 394
2024
Q3 		$0 Buy
+100
New +$282 ﹤0.01% 814

Other funds holding TNYA

CG
Column Group San Francisco, California $101M AUM 290.34% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EC
Euclidean Capital New York $392M AUM 31.85% 1-Year Est. Return

AlphaMark Advisors's TNYA Position: Q4 2024 in Review

AlphaMark Advisors increased its Tenaya Therapeutics (TNYA) stake by 10,500% in Q4 2024, buying an estimated $23.5K and bringing the position to 10,600 shares worth $15K. The position accounts for 0.01% of the portfolio, ranked #394.

AlphaMark Advisors first reported a position in TNYA in Q3 2024 and has held it in 2 quarters since. 88 funds tracked by Wall St. Rank hold TNYA as of Q4 2024.

  • AlphaMark Advisors held 10,600 shares of Tenaya Therapeutics worth $15K as of Q4 2024.
  • AlphaMark Advisors bought 10,500 Tenaya Therapeutics shares in Q4 2024, an estimated $23.5K.
  • Tenaya Therapeutics made up 0.01% of AlphaMark Advisors's portfolio in Q4 2024, its #394 holding.
  • AlphaMark Advisors first reported a position in Tenaya Therapeutics in Q3 2024 and has held it in 2 quarters since.
  • 88 funds tracked by Wall St. Rank held Tenaya Therapeutics as of Q4 2024.

Based on AlphaMark Advisors's 13F filing for Q4 2024, filed 21 Jan 2025.